Cough medicine may help rare diseases: global registry launched

NCT ID NCT04388969

First seen Apr 30, 2026 · Last updated May 15, 2026 · Updated 2 times

Summary

This study creates a registry to collect safety and effectiveness information on ambroxol, a common cough medicine, when used off-label at higher doses for Gaucher disease or GBA-related Parkinson's. Researchers aim to gather data from 300 patients worldwide to help doctors and families make informed decisions. No new treatment is being tested; instead, the focus is on learning from real-world use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shaare Zedek Medical Center

    RECRUITING

    Jerusalem, Please Select..., 9103102, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shaare Zedek Medical Center

    RECRUITING

    Jerusalem, Israel

  • Shaare Zedek Medical Center

    RECRUITING

    Jerusalem, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.